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Abstract Treatment of IPC-81 cells led to inhibition of protein
synthesis, which was accompanied by an increase in the average
size of polysomes and a decreased rate of elongation, indicating
that it involved inhibition of peptide chain elongation. This
inhibition was also associated with increased phosphorylation of
elongation factor eEF2 (which inhibits its activity) and enhanced
Ca2+/calmodulin-independent activity of eEF2 kinase. Previous
work has shown that phosphorylation of eEF2 kinase by cAMP-
dependent protein kinase (cAPK) in vitro induces such activator-
independent activity, and the present data show that such a
mechanism can occur in intact cells to link physiological levels of
cAPK activation with inhibition of protein synthesis.
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1. Introduction
mRNA translation is subject to acute regulation under a
wide variety of conditions, and this is thought to involve,
primarily, changes in the activity or availability of translation
initiation or elongation factors, which in turn are mediated
through alterations in their states of phosphorylation [1^4].
The role of cAMP-dependent protein kinase (cAPK) in the
regulation of translation in intact cells has not been ¢rmly
established [5^7]. Although several translation initiation fac-
tors (e.g. eIF3, eIF4A, eIF4B, eIF4G) have been reported to
be in vitro substrates for cAPK [1,8], the biological signi¢-
cance of such in vitro phosphorylation is unclear.
There is also a sophisticated system for regulating peptide
chain elongation [9] (for reviews, see [1,10]). The best studied
example of the acute control of elongation involves inactiva-
tion of elongation factor 2 (eEF2), a protein required for
translocation of peptidyl-tRNAs from the A-site to the P-
site [11^13]. eEF2 can be phosphorylated and inactivated by
a dedicated eEF2 kinase (also known as Ca2/calmodulin-de-
pendent kinase III), which so far appears to have eEF2 as its
only substrate [13,14]. This kinase and myosin heavy chain
kinase A are so far the only known members of a unique
kinase family whose ATP binding site is the only sequence
motif shared with other eukaryotic protein kinases [9]. Anoth-
er pathway for inhibition of eEF2, ADP ribosylation, is also
remarkably dedicated to eEF2 regulation [5,15]. The question
of whether control of elongation is physiologically important
has remained largely unanswered, but it was recently demon-
strated that insulin stimulates protein synthesis by enhancing
elongation through dephosphorylation of eEF2 [16].
In the present study we have investigated the e¡ects of
cAMP on protein synthesis and speci¢cally peptide chain
elongation, in intact cells. We were prompted to do this by
the observation that, in vitro, cAPK can phosphorylate and
activate eEF2 kinase (by rendering its activity partially inde-
pendent of Ca ions) [17]. It was a high priority to study
whether physiological levels of cAPK activation can regulate
eEF2 kinase in intact cells and whether this led to modulation
of the rate of elongation. For our work, we used the IPC-81
cell line which has been used extensively in studies on the anti-
growth e¡ects of cAMP [18]. Furthermore, IPC-81 cell clones
expressing a mutant of cAPK which responds poorly to
cAMP are available [19]. The data indicate that cAMP regu-
lation of eEF2 kinase operates to regulate peptide chain elon-
gation in intact cells.
2. Materials and methods
2.1. Model system
Rat myeloid IPC-81 cells were cultured at densities of around
5U105 cells/ml in Dulbecco’s modi¢ed Eagle’s medium (DMEM) sup-
plemented with 8% horse serum [20]. The IPC-RID336 cAMP-resistant
clone was isolated as described by [19]. Apoptosis-resistant bcl-2-
transfected IPC-81 cells (IPC-81bcl2) were used in some experiments.
cAPK was activated by adding the cAMP analog 8-(4-chlorophenyl-
thio)-cAMP (8-CPT-cAMP) to the growth medium.
2.2. Determination of protein synthesis
At the start of the experiment, the cells (IPC-81wt, IPC-81bcl2 or
IPC-RID336) were shifted to CO2-equilibrated and methionine-free
DMEM containing 2% horse serum. The cAMP agonist 8-CPT-
cAMP (100 WM ¢nal concentration) or the cAMP antagonist Rp-8-
Br-cAMPS (200 WM ¢nal concentration) was added to the medium 1 h
before cell harvesting. 15 min before harvesting each well was sup-
plemented with 7.5 WCi [35S]methionine (Amersham SJ1515). After
centrifugation (1100Ug for 2 min at 4‡C) the cell pellets were resus-
pended and lysed in ice-cold 50 mM Tris-HCl pH 7.5 containing 1%
Nonidet-P40, 100 mM NaCl, 2 mM EDTA and a protease inhibitor
cocktail (0.7 Wg/ml chymostatin, 0.6 Wg/ml antipain, 5 Wg/ml leupeptin
and 1.4 Wg/ml pepstatin). The lysates were centrifuged at 16 000Ug for
10 min, and the proteins in the supernatant were precipitated by add-
ing trichloroacetic acid (TCA) to 10% ¢nal concentration. The pre-
cipitate was ¢ltered through GF-C ¢lters (Whatman), washed three
times with 1 ml 10% TCA and ¢nally with 1 ml 96% ethanol. The
¢lters were air-dried and counted in scintillant. Cumulative pro-
tein synthesis was measured by a similar procedure, but with
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[35S]methionine present in the growth medium from the start of the
experiment.
2.3. Polysomal pro¢le analysis and morphometric evaluation of
polysome size
Cells were resuspended in 1 ml K bu¡er (20 mM Tris-HCl pH 7.6,
120 mM KCl and 7 mM MgSO4) and lysed by adding Triton X-100
to 0.4% ¢nal concentration. Nuclei and membrane-bound ribosomes
were removed by centrifugation at 6000Ug for 10 min. Ribosomes
from approximately 1.5U107 cells were fractionated on a linear su-
crose gradient as described [21]. IPC-81 cells were also prepared for
electron microscopy [17], and membrane-bound and free polysomes
were quantitated by morphometric analysis, as described by Gunders-
en [22]. Polysomes were studied in series of sections, and particles
were sampled using a random plane with identical probabilities, irre-
spective of particle size.
2.4. Estimation of elongation rate
The e¡ect of cAMP treatment on the ribosomal transit time was
measured as described [23]. This involves the separate determination
of the cumulative [35S]methionine incorporation into the free ribo-
some fraction (containing completed protein chains) compared with
total cellular protein (containing both completed and un¢nished pro-
teins).
2.5. Determination of eEF2 phosphorylation by Western blotting after
2D-PAGE
Cell lysates were prepared using a EMBL-made cell cracker (a
metal cylinder with an internal diameter of 8.020 mm containing a
metal bead with a diameter of 8.006 mm) with a bu¡er containing
both protease and phosphatase inhibitors (15 mM HEPES pH 7.5, 2.3
mM MgCl2, 120 mM KCl, 1 mM dithiothreitol, 1 mM benzamidine,
1 mM sodium orthovanadate, 1 mM ATP, 1 mM pyrophosphate,
1 WM microcystin and the protease inhibitor cocktail (see above)).
Before isoelectric focusing (¢rst dimension protein separation),
samples were diluted 1:4 in 2D bu¡er containing 9.8 M urea,
100 mM 1,4-dithioerythritol, 1.5% v/v Pharmalyte (Pharmacia) pH
3.5^10, 0.5% v/v Pharmalyte pH 5^6, 4% w/v CHAPS (3-[(3-cholami-
dopropyl)dimethylammonio]-1-propanesulfonate) and 0.2% w/v SDS.
The two-dimensional sample separation was done as described [24]
using a linear immobilized pH 3^10 gradient (Pharmacia) for the ¢rst
dimension run and 7.5% SDS-PAGE for the second dimension run.
After completion of the gel run, the proteins were transferred to nitro-
cellulose membranes by electroblotting for 70 h at 15 V and 4‡C.
Blots were incubated with anti-eEF2 antibody [25] followed by alka-
line phosphatase-conjugated goat anti-rabbit antibody (Promega).
The blots were developed using BCIP/NBT (Sigma) as substrate.
2.6. eEF2 kinase assay
The Ca2/calmodulin-dependent and -independent activities of
eEF2 kinase in lysates from cAMP-stimulated cells were measured
as previously described [16,26]. Reactions were stopped in standard
SDS-PAGE sample bu¡er, and the proteins were separated on a 10%
SDS gel followed by autoradiography. Control assays were also per-
formed in which the eEF2 was omitted. The radioactivity associated
with the band corresponding to eEF2 was quanti¢ed using an HP
Instant Imager.
3. Results
3.1. Activation of cAMP kinase in cells inhibits translation
elongation
Protein synthesis in IPC-81 wild type cells immediately
started to decline after 8-CPT-cAMP challenge (data not
shown), and the maximal 27% inhibition of protein synthesis
was seen after 1 h (Fig. 1A). A similar e¡ect of 8-CPT-cAMP
was noted in apoptosis-resistant bcl-2-transfected cells. To
exclude the possibility that the e¡ect observed could be due
to inhibition of amino acid uptake by cAMP, continuous
[35S]methionine labelling experiments were also performed.
In both untreated and cAMP-treated cells the rate of
[35S]methionine incorporation was linear during the ¢rst
hour, but in cAMP-treated cells the degree of labelling was
reduced by one third compared to the untreated cells (data
not shown).
In order to assess the degree of cAPK activation required to
regulate protein synthesis, experiments were performed using
the cAPK inhibitor Rp-8-Br-cAMPS. This is the most potent
and speci¢c inhibitor known for the type I isozyme of cAPK
which is the predominant type of cAPK in IPC-81 cells, and is
able to depress cAPK activity below the basal resting level
[24]. Rp-8-Br-cAMPS appeared to enhance protein synthesis
(Fig. 1B) in the absence of added cAMP analogue, indicating
that even the basal level of cAPK activity was su⁄cient to
exert some tonic inhibition of protein synthesis.
To get additional proof that cAMP acted via cAPK to
depress protein synthesis, experiments were performed using
the cAMP-resistant IPC-RID336 cells. These cells express both
normal and mutated RIK subunit of cAPK, the mutation
having a dominant-negative e¡ect [19]. The dominant RID336
is expressed in a high enough quantity to sequester 65% of the
catalytic subunit of cAPK, leaving about a third of the cAPK
free for normal regulation by cAMP [19]. Even in these cells,
Rp-8-Br-cAMPS enhanced protein synthesis (Fig. 1B), sug-
gesting that protein synthesis was regulated at levels of
cAPK activation less than 35% of maximal. Protein synthesis
in IPC-RID336 cells was little a¡ected by concentrations of 8-
CPT-cAMP in the range 0^100 WM (Fig. 1A), which is the
range where activation of cAPK beyond 35% is blocked e⁄-
ciently by RID336. RID336 requires about 30-fold more 8-CPT-
cAMP to release the catalytic subunit than is the case for wild
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Fig. 1. The e¡ect of a cAPK agonist (100 WM 8-CPT-cAMP, panel
A) and a cAPK antagonist (200 WM Rp-8-Br-cAMPS, panel B) on
total protein synthesis in IPC-81wt cells, apoptosis-resistant IPC-
81bcl2 cells and cAMP-subresponsive IPC-RID336 cells. The S.E.M.
and n are indicated. In Fig. 1B the level of protein synthesis with
95% con¢dence intervals was as follows: IPC-81wt cells 121 þ 21%,
IPC-81bcl2 cells 118 þ 16% and IPC-RID336 cells 114 þ 12%. The level
of protein synthesis in control cells is indicated by the broken line.
Table 1
Morphometric assessment of polysome size on electron micrographs
of cells treated with 8-CPT-cAMP for 1 h and control IPC-81 cells
Fraction of polysomes with n ribosomes
n = 3^4 n = 5^6 ns 7
Control 0.52 þ 0.04 0.33 þ 0.10 0.15 þ 0.07
cAMP 0.25 þ 0.07 0.31 þ 0.03 0.44 þ 0.07
The standard error is based on three experiments.
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type RI, and its e¡ect can be relieved by millimolar concen-
trations of 8-CPT-cAMP in the intact cell [19]. In fact, at
3 mM 8-CPT-cAMP, protein synthesis in the mutant cells
was as inhibited as at 100 WM 8-CPT-cAMP for the wild
type cells (data not shown). It can be concluded that cAPK
is responsible for the observed e¡ects of the cAMP analog and
that cAPK modulates protein synthesis at low, physiological
degrees of activation.
Having shown that cAPK inhibited translation in the intact
cell, the next step was to ¢nd out if this inhibition occurred at
the level of initiation or elongation. As an initial investigation,
polysomal pro¢les were studied (Fig. 2). A recruitment of free
ribosomes into polysomes was found, and the number of very
long polysomes in particular increased (Fig. 2), a ¢nding
which was con¢rmed by morphometric evaluation of the num-
ber of ribosomes per polysome on electron micrographs (Ta-
ble 1). The combination of accumulation of polysomes and
diminished protein synthesis strongly suggests inhibition of
elongation.
It was important to determine if the extent of protein syn-
thesis inhibition estimated above could be explained by elon-
gation inhibition alone, i.e. if the degree of elongation inhib-
ition corresponded to the degree of protein synthesis
inhibition in pulse-labelling experiments. For this, the actual
elongation rate had to be measured. Such measurements were
performed in control cells and in cells pre-treated for 1 h with
cAMP analog (Fig. 3). The average mRNA transit time in
control cells was around 3 min. We found that cAMP treat-
ment increased the average transit time from 3 to 5 min, i.e. it
reduced the average elongation rate by approximately 40%
(Fig. 3). However, our data are insu⁄cient to give a statisti-
cally signi¢cant di¡erence in transit time between control and
cAMP-treated cells. This reduction in elongation rate can
fully explain the reduction of protein synthesis found in
pulse-labelling experiments (Fig. 1) and extended labelling ex-
periments (data not shown).
3.2. cAMP treatment of cells causes
Ca2+/calmodulin-independent activation of eEF2 kinase
A molecular mechanism for cAMP-induced inhibition of
elongation has already been suggested by Redpath and Proud
[17]. They found that the catalytic subunit of cAPK phos-
phorylated and activated puri¢ed eEF2 kinase, making its
activity Ca2/calmodulin-independent. To investigate if this
was also the case in intact cells, lysates from control and
cAMP-stimulated IPC-81 cells were prepared and assayed
for eEF2 kinase activity, using puri¢ed eEF2 as substrate
(Fig. 4A). After autoradiography, the [32P]phospho-eEF2
was quanti¢ed by direct measurement of radiolabelling. In
lysates from unstimulated cells, the activity with 1 mM
EGTA was about 10% of that in the presence of Ca2/cal-
modulin. This Ca2/calmodulin-independent activity increased
in lysates from cells treated with cAMP for 15 min or longer
to reach half the level observed with Ca2/calmodulin (Fig.
4A). The maximal activity of eEF2 kinase measured in the
presence of Ca2/calmodulin was similar at all time points
studied, indicating that the total amount of enzyme did not
change.
Activation of eEF2 kinase is expected to lead to increased
phosphorylation of the cellular eEF2. This was investigated
on Western blots prepared after 2D gel electrophoresis of
cytoplasmic proteins probed with rabbit anti-eEF2 antibodies
(Fig. 4B). Care was taken to avoid proteolysis and dephos-
phorylation during preparation of the cell lysates. Various
forms of eEF2 can be separated by isoelectric focusing [27]
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Fig. 3. Estimation of average ribosomal transit time. The short-term
cumulative incorporation of [35S]methionine was measured in the
combined polysomal and free fraction (open symbols), and the free
protein fraction only, i.e. the fraction with completed protein chains
(¢lled symbols), in control cells (a) and cAMP-stimulated cells (E).
The data points represent an average of three experiments and
the S.E.M. are indicated. Linear lines showing the rate of
[35S]methionine incorporation in the total and free fractions were
drawn and extrapolated to the abscissa to ¢nd the half average
transit time. In this case, the half average transit time was 1.5 min
for control cells (A) and 2.5 min for cAMP-stimulated cells (B). For
the theoretical basis for such calculations, see [12].
Fig. 2. A typical polysome sedimentation pro¢le from control cells
and cells 1 h after cAMP challenge, measured by absorbance at 260
nm, and representing one of four experiments. The shaded area il-
lustrates the increase in longer polysomes seen after a direct overlay
of the two pro¢les. The position of free ribosomal subunits and the
smaller polysomes (with 2^6 ribosomes per mRNA) is indicated.
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or by 2D gel electrophoresis [28]. In theory, six di¡erent mo-
bility forms of eEF2 can be expected, i.e. eEF2 with and
without the His-714 to diphthamide modi¢cation in un-,
mono- and biphosphorylated forms. This was also what we
observed. In the control cell lysates, eEF2 antibodies recog-
nized ¢ve spots, and in the lysates from cAMP-treated cells, a
sixth even more acidic spot appeared (Fig. 4B). There was a
clear shift towards the more acidic forms of eEF2 with cAMP
treatment, and after such treatment the less acidic (unphos-
phorylated) forms constituted only a small fraction of the
total. It should also be noted that a substantial portion of
eEF2 appeared to be phosphorylated even in control cell ly-
sates, indicating that IPC-81 cells may have a basal eEF2
kinase activity that is higher or a phospho-eEF2 phosphatase
activity which is lower than what has previously been found in
reticulocyte lysates, Swiss 3T3 cells, Chinese hamster ovary
cells, hepatocytes [27] or human amnion cells [28].
4. Discussion
We report that activation of cAMP-dependent protein ki-
nase inhibited protein synthesis in leukemia cells through re-
tardation of the rate of polypeptide chain elongation (Figs. 1^
3). The degree of inhibition of elongation (40%, Fig. 3) cor-
responded with the degree of inhibition of protein synthesis
(Fig. 1), and was accompanied by increased phosphorylation
of eEF2 (Fig. 4B). This prompted us to study eEF2 kinase,
which is usually dependent on Ca2/calmodulin for its activity
[29], but which shows Ca2/calmodulin-independent activity
in vitro after incubation with puri¢ed cAPK [17]. The present
study showed that cAMP stimulation did indeed lead to eEF2
kinase becoming partially independent of Ca2/calmodulin in
intact cells (Fig. 4A), indicating that eEF2 kinase is a bio-
logically relevant target for cAPK. The phosphorylation of
eEF2 kinase did not require massive stimulation of cAPK,
since the enzyme appeared to be partially activated in control
cell lysates under calcium-free conditions (Fig. 4A). This cor-
relates with our data showing that even the basal cAPK ac-
tivity was enough to exert some tonic inhibition of protein
synthesis, as revealed by experiments showing enhancement
of protein synthesis when the basal cAPK activity was de-
creased by Rp-8Br-cAMPS (Fig. 1B). This may also explain
why the basal average ribosomal transit time (Fig. 3) was
somewhat longer than what has generally been reported [23].
When searching the protein sequence of eEF2 kinase for a
consensus substrate sequence for cAPK, residues 147^155
(RTKKLSNFL) were found to represent a potential phos-
phorylation site [30]. This sequence is identical in eEF2 kinase
from rat, mouse and man, and in Caenorhabditis elegans eEF2
kinase a similar sequence (RLKKCSKHG) is found with con-
servation of both the upstream basic residues (underlined) and
the serine residue. Two other potential cAPK phosphorylation
sites were suggested by Redpath et al. [30], but they lack
conservation of either the serine residue or the upstream argi-
nine residue. When assayed as a substrate for the puri¢ed
catalytic subunit of cAPK, the Km of the synthetic peptide
RTKKLSNFL was found to be 610 WM and the Vmax=2.8
s31 (data not shown). This points to Ser-152 as the most
probable site for the 1:1 stoichiometric phosphorylation of
eEF2 kinase previously observed. Although the Km for the
peptide was 80-fold higher than for puri¢ed eEF2 kinase,
the Vmax was higher [17]. This indicates that the phosphory-
lation site may be less accessible in eEF2 kinase than in the
synthetic peptide, and that eEF2 kinase provides additional
contacts improving the a⁄nity for the catalytic subunit of the
cAPK.
The teleological signi¢cance of cAMP-induced inhibition of
elongation is uncertain. Translation was inhibited by concen-
trations of cAMP which were too low to induce apoptosis,
inhibition occurred well before the onset of apoptosis, and
was also observed in bcl-2-transfected cells protected from
cAMp-induced apoptosis (Fig. 1). Any major change in the
pattern of proteins observed after two-dimensional gel electro-
phoresis has not been found (data not shown). Since cAMP
induces growth arrest of IPC-81 cells [18,31], it is possible that
the decline in protein synthesis represents an adjustment to a
lower rate of proliferation. cAMP-induced inhibition of elon-
gation has also been found in glucagon-stimulated rat liver
cells, where the average polypeptide completion time increased
from 1.5 min to 2.4 min after intraperitoneal injection of
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Fig. 4. A: The Ca2/calmodulin-independent activity of eEF2 kinase
in IPC-81 lysates from untreated and cAMP-treated cells (lower
panel) compared to the Ca2/calmodulin-dependent (total) eEF2
kinase activity (upper panel). Lysates were prepared from control
cells and cells treated with cAMP for 15 min to 2 h, and assayed
for eEF2 kinase activity using puri¢ed rabbit reticulocyte eEF2 as
substrate. The positions of molecular weight markers are shown on
the left. The extent of radiolabel incorporated into the substrate
(eEF2) was quanti¢ed by a HP Instant Imager. The percentage of
Ca2/calmodulin-independent activity related to an averaged total
activity is indicated below the panel. B: Western blots of gels with
proteins from control (upper panel) and 8-CPT-cAMP-treated (low-
er panel) cells separated by two-dimensional gel electrophoresis and
probed with anti-eEF2 antibodies. eEF2 isoforms in a control cell
lysate are directly compared with eEF2 isoforms in a lysate from
cells treated with cAMP for 1 h. The two blots were aligned accord-
ing to the background spots.
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glucagon [32]. In this situation a transient reduction in protein
synthesis may make more amino acids available as precursors
for gluconeogenesis. Whatever the purpose, it is clear that
cAMP-induced elongational inhibition is not restricted to
myeloid leukemia cells. In this setting it may seem puzzling
that cAMP decreased, rather than increased, the activity of
eEF2 kinase in PC12 cells, but this decrease was due to loss of
enzyme, as assayed in the presence of Ca2/calmodulin, and
was a late occurring phenomenon [33,34]. In the IPC-81 cells
no loss of total eEF2 kinase activity was noted (Fig. 4A).
It is of interest that the trophic hormone insulin, which
antagonizes the action or e¡ects of cAMP with respect to a
number of cell functions [3,18], also has the opposite e¡ect to
cAMP on the control of elongation. Notably, insulin de-
creased eEF2 kinase activity in CHO cells in a rapamycin-
sensitive manner [16]. A coupling between the retardation of
elongation and anti-trophic states of cells was also observed in
excitotoxic induction of delayed neuronal cell death. This was
preceded by a persistent inhibition of protein synthesis which,
at least initially, was caused by eEF2 kinase activation by
Ca2 in£ux [35]. In this model system for apoptosis, the
eEF2 kinase activity remained strictly Ca2/calmodulin-de-
pendent. However, a linkage between elongation retardation
and anti-trophic states is not always observed since eEF2
kinase activation coupled with elongational inhibition has
also been reported in mitogen-stimulated cells and in prolif-
erating glioma cells [36,37].
In conclusion, the present work adds cAMP-dependent pro-
tein kinase to the list of modulators of translation in intact
cells, which exerts its e¡ect on the level of elongation. Thus, in
addition to calcium, cAMP can act as an alternative second
messenger activator of eEF2 kinase and hence of the phos-
phorylation and inactivation of eEF2. The physiological im-
portance of regulating elongation is not known.
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